A 4-Week Randomized, Double-Blind, Placebo-Controlled, Phase 2a Safety and PK Study of Oral ELND005 in Young Adults With Down Syndrome Without Dementia.
Phase of Trial: Phase II
Latest Information Update: 11 Feb 2016
At a glance
- Drugs ELND 005 (Primary)
- Indications Down syndrome
- Focus Adverse reactions; Therapeutic Use
- Sponsors Elan Pharma International; Elan Pharmaceuticals
- 01 Dec 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 07 Apr 2014 This trial is close to completing enrolment, and data are expected in quarter 3, 2014, according to a Transition Therapeutics media release.
- 29 Jan 2014 Planned End Date changed from 1 Jul 2014 to 1 Apr 2014 as reported by ClinicalTrials.gov record.